Physician profile
Erisa Gjinaj
NPI 1881331452
$660.09
in general payments reported to CMS, 2019-2025
15 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $165 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $111.92 | 2024 | |
| Exact Sciences Corporation | $92.27 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.87 | 2025 | Xifaxan |
| Ardelyx, INC. | $64.15 | 2025 | Ibsrela |
| Pfizer INC. | $45.71 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $41.45 | 2025 | Eliquis |
| Abbvie INC. | $34.75 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.44 | 2025 | Caplyta |
| Novo Nordisk INC | $32.06 | 2024 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $24.10 | 2025 | Nexletol |
| Lilly USA, LLC | $22.69 | 2025 | Zepbound, Mounjaro |
| Aimmune Therapeutics, INC. | $22.57 | 2025 | Zenpep |
| Actelion Pharmaceuticals US, INC. | $21.67 | 2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.47 | 2025 | Jardiance |
| Sanofi Pasteur INC. | $20.97 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erisa Gjinaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.